Skip to content

Research at St Andrews

Emergent resistance to dolutegravir among INSTI-naïve patients on first-line or second-line antiretroviral therapy: a review of published cases

Research output: Contribution to journalReview articlepeer-review

DOI

Open Access permissions

Open

Author(s)

Muge Cevik, Chloe Orkin, Paul E Sax

School/Research organisations

Abstract

None of the licensing studies of dolutegravir (DTG) reported any treatment-emergent resistance among DTG-treated individuals, though virological failure in treatment-naïve and treatment-experienced, integrase strand transfer inhibitor (INSTI)-naïve individuals has been reported in clinical practice. While the spectrum of dolutegravir-selected mutations and their effects on clinical outcome have been described, the clinical characteristics of these rare but important virological failure cases are often overlooked. In this perspective piece, we focus on key clinical aspects of emergent resistance to DTG among treatment-naïve and treatment-experienced INSTI-naïve patients, with an aim to inform clinical decision-making. Poor adherence and HIV disease factors contribute to emergent drug resistance, even in regimens with high resistance barriers. Patients with severe immunosuppression or poor adherence are under-represented in licensing studies, and these patients may be at higher risk of treatment failure with DTG resistance, which requires close clinical and laboratory follow-up.

Close

Details

Original languageEnglish
Article numberofaa202
Number of pages4
JournalOpen Forum Infectious Diseases
Volume7
Issue number6
Early online date2 Jun 2020
DOIs
Publication statusPublished - Jun 2020

    Research areas

  • Dolutegravir, HIV, Treatment failure, Treatment-naïve, Resistance

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Expect the unexpected – implications for next phase of COVID-19 response

    Clifford, S., Cevik, M., Campbell, R., O’Shea, D. & Sutherland, R., Jun 2021, In: Infection Prevention in Practice. 3, 2, 100118.

    Research output: Contribution to journalArticlepeer-review

  2. A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

    Tweed, C. D., Wills, G. H., Crook, A. M., Amukoye, E., Balanag, V., Ban, A. Y. L., Bateson, A. L. C., Betteridge, M. C., Brumskine, W., Caoili, J., Chaisson, R. E., Cevik, M., Conradie, F., Dawson, R., del Parigi, A., Diacon, A., Everitt, D. E., Fabiane, S. M., Hunt, R., Ismail, A. I. & 19 others, Lalloo, U., Lombard, L., Louw, C., Malahleha, M., McHugh, T. D., Mendel, C. M., Mhimbira, F., Moodliar, R. N., Nduba, V., Nunn, A. J., Sabi, I., Sebe, M. A., Selepe, R. A. P., Staples, S., Swindells, S., van Niekerk, C. H., Variava, E., Spigelman, M. & Gillespie, S. H., 1 Apr 2021, In: International Journal of Tuberculosis and Lung Disease. 25, 4, p. 305-314 10 p.

    Research output: Contribution to journalArticlepeer-review

  3. What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol

    Sigfrid, L., Cevik, M., Jesudason, E., Lim, W. S., Rello, J., Amuasi, J., Bozza, F., Palmieri, C., Munblit, D., Holter, J. C., Kildal, A. B., Reyes, L. F., Russell, C. D., Ho, A., Turtle, L., Drake, T. M., Beltrame, A., Hann, K., Bangura, I. R., Fowler, R. & 17 others, Lakoh, S., Berry, C., Lowe, D. J., McPeake, J., Hashmi, M., Dyrhol-Riise, A. M., Donohue, C., Plotkin, D., Hardwick, H., Elkheir, N., Lone, N. I., Docherty, A., Harrison, E., Baille, J. K., Carson, G., Semple, M. G. & Scott, J. T., Mar 2021, In: BMJ Open. 11, 3, 8 p., e043887.

    Research output: Contribution to journalArticlepeer-review

  4. COVID-19, children and schools: overlooked and at risk

    Munro, A., Bowen, A. C. & Cevik, M., 28 Feb 2021, In: Medical Journal of Australia. 214, 4, p. 188

    Research output: Contribution to journalLetter

  5. How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19

    Accorsi, E. K., Qiu, X., Rumpler, E., Kennedy-Shaffer, L., Kahn, R., Joshi, K., Goldstein, E., Stensrud, M. J., Niehus, R., Cevik, M. & Lipsitch, M., 25 Feb 2021, In: European Journal of Epidemiology. 18 p.

    Research output: Contribution to journalReview articlepeer-review

Related by journal

  1. Corrigendum to: Transfusion-transmitted malaria: a systematic review and meta-analysis (Open Forum Infectious Diseases (2019) 6:7 (ofz283) DOI: 10.1093/ofid/ofz283)

    Ahmadpour, E., Foroutan-Rad, M., Majidiani, H., Moghaddam, S. M., Hatam-Nahavandi, K., Hosseini, S-A., Rahimi, M. T., Barac, A., Rubino, S., Zarean, M., Mathioudakis, A. G. & Cevik, M., Jan 2020, In: Open Forum Infectious Diseases. 7, 1, 1 p., ofz540.

    Research output: Contribution to journalComment/debatepeer-review

  2. Longitudinal PKPD biomarkers correlate with treatment outcome in drug sensitive pulmonary tuberculosis; a population pharmacokinetic-pharmacodynamic analysis

    Kloprogge, F., Mwandumba, H. C., Kamdolozi, M., Banda, G., Shani, D., Corbett, E. L., Kontogianni, N., Ward, S., Khoo, S. H., Davies, G. R. & Sloan, D. J., Jul 2020, In: Open Forum Infectious Diseases. 7, 7, 11 p., ofaa218.

    Research output: Contribution to journalArticlepeer-review

  3. Transfusion-transmitted malaria: a systematic review and meta-analysis

    Ahmadpour, E., Foroutan-Rad, M., Majidiani, H., Moghaddam, S. M., Hatam-Nahavandi, K., Hosseini, S-A., Rahimi, M. T., Barac, A., Rubino, S., Zarean, M., Mathioudakis, A. G. & Cevik, M., Jul 2019, In: Open Forum Infectious Diseases. 6, 7, 8 p., ofz283.

    Research output: Contribution to journalArticlepeer-review

ID: 269436080

Top